Orano - Annual Activity Report 2025 319 FINANCIAL STATEMENTS 6 Consolidated financial statements – financial year ended December 31, 2025 Consolidated statement of changes in equity (in millions of euros) Notes Number of shares Capital Consolidated premiums and reserves Revaluation of the net liability in respect of defined- benefit obligations Unrealized gains and losses on financial instruments Currency translation reserves Total equity attributable to owners of the parent Noncontrolling interests Total equity January 1, 2024 264,152,778 132 1,478 (143) 58 23 1,550 387 1,937 Net income for the period 633 633 78 712 Other items of comprehensive income 8 13 (161) 36 (113) (23) (136) Comprehensive income 633 13 (161) 36 521 55 576 Dividends paid – (84) (84) Capital increase 22 9,146,340 5 292 297 297 Other changes (1) (12) 12 – – 10 10 DECEMBER 31, 2024 273,299,118 137 2,393 (118) (103) 59 2,367 369 2,736 Net income for the period 404 404 145 550 Other items of comprehensive income 8 52 223 (224) 52 (8) 44 Comprehensive income 404 52 223 (224) 456 138 594 Dividends paid (25) (25) (91) (115) Other changes (2) 204 1 1 207 105 312 DECEMBER 31, 2025 273,299,118 137 2,976 (64) 120 (164) 3,005 521 3,526 (1) At December 31, 2024, other changes of 10 million euros correspond to the deconsolidation of non-controlling interests in companies in Niger. (2) At December 31, 2025, other changes for 312 million euros correspond to the acquisition by Sanofi of a 15.6% stake in Orano Med Theranostics for 295 million euros and the loss of control of Nurlikum Mining for 16 million euros (see Note 1.1).
RkJQdWJsaXNoZXIy NzMxNTcx